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Early results of the Endurant endograft system in
patients with friendly and hostile infrarenal
abdominal aortic aneurysm anatomy
George S. Georgiadis, MD,a George Trellopoulos, MD,b George A. Antoniou, MD,a
Konstantinos Gallis, MD,b Evagelos S. Nikolopoulos, MD,a Konstantinos C. Kapoulas, MD,a
Xanthi Pitta, MD,b and Miltos K. Lazarides, MD, EBSQvasc,a Alexandroupolis and Thessaloniki, Greece
Objective: To evaluate and compare the outcome after endovascular abdominal aortic aneurysm repair (EVAR) with the
newly released Endurant endograft system in patients with different aortoiliac anatomic characteristics.
Methods: We conducted a prospective observational study assigning patients with infrarenal abdominal aortic aneurysm
(AAA) treated with the Endurant endoprosthesis from February 2009 to March 2010. Two groups were studied,
according to the presence of a friendly (group I [GI] 43) or hostile (group II [GII] 34) infrarenal aortoiliac anatomy.
Hostile profile was defined as any (or combination) of the following measurements: 5 mm< proximal neck length (Lpr)
<12 mm, 60° < proximal neck angle (Aopr) <90° and 60° < any iliac axis angle (Aoiliac) <90°. Primary end points
included technical and clinical success, freedom from early or late secondary interventions, any type of endoleak, and
aneurysm-related death. All outcome measures were calculated using the Kaplan-Meier method and the log rank test was
applied for comparisons between the groups.
Results: The mean comorbid severity scoring was higher in GII (P .018). The mean follow-up period in GI and GII was
12.9  3.9 months (SD, range: 6.4-19.8) and 12.4  4 months (range: 4.2-19.6), respectively. Two unplanned
conversions to aortouniiliac configurations were required in GI. The technical success rate in GI and GII was 95.4% and
100%, respectively. The requirement for intentional occlusion of the internal iliac artery, the requirement for cross-limb
technique, the necessity of troubleshooting techniques, the procedure and radiation times, the frequency of postimplan-
tation syndrome, and mean hospital stay were significantly higher in GII (P  .028, P  .013, P  .005, P  .037, P <
.001, P .032, P .021, respectively). Two patients of GI died in the early postoperative period (one aneurysm but not
device-related death), whereas no deaths in GII were recorded, yielding an overall 30-day mortality rate of 2.3%. No type
I/III endoleaks were recorded up to the end of the study. Freedom from any type of endoleak, early or late secondary
interventions, and aneurysm-related death at 12 months were found in 93.2%, 87.1%, and 93.3% of GI patients;
respective values for GII were 86% (P .21), 93.4% (P .066), and 93.4%. The clinical success rate was 82.1% and 100%
at 12 months for GI and GII, respectively.
Conclusions: Early (12 months) results suggest similar clinical performance of the Endurant stent graft system in
endovascular treatment of AAAs with friendly and hostile anatomies, however, demonstrating more intra- and
perioperative adversities for the last group. Larger prospective studies or even randomized trials comparing different new
generation graft models are required to evaluate the comparable long-term results and possible expansion of EVAR
indications for this specific endograft in adverse anatomies. ( J Vasc Surg 2011;54:616-27.)
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has been increasingly used in the management of aneu-
rysms and is widely accepted as a less invasive alternative
treatment to traditional open surgical repair.1,2 Over the
last few years, technological advancements and further clin-
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616cal research have mainly focused on the development and
ntroduction of new generation stent graft devices, such as
hose with enhanced flexibility to overcome challenging
natomies.3-11 Hostile infrarenal aortic anatomy is a major
ause of failure of EVAR12-17 and for that reason a signifi-
ant proportion of patients with adverse aneurysm mor-
hology still benefit from conventional open repair. Unfa-
orable anatomical conditions, such as severe infrarenal
ortic neck angulation (60°) and dilated aortic neck, are
ssociated with a high incidence of proximal type I en-
oleak17 and stent graft migration,17,18 respectively. Other
natomical limitations, such as a very short proximal neck
nd severe angulation of the iliac arteries have also been
escribed. Cumulative clinical experience and technical
dvances with the evolution of newer more flexible stent
raft devices3,5,7-9,19,20 have all been working together to
ircumvent adverse aneurysm morphologies, with a view to
xpanding the applications of endovascular treatments for
ortic aneurysms. Recently, late generation stent grafts, like
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device, have been developed to overcome complex aortic
morphologies and improve EVAR outcomes.3-11,19,20 A pro-
spective, multicenter, controlled trial experience revealed that
the Endurant system was associated with no postoperative
aneurysm ruptures or aneurysm-related mortalities at 1 year
and with no mortalities from any cause at 30 days. It is
currently under review by the FDA for premarket approval.21
Its long-term performance in a real world population from a
multicenter prospective study enrolling1200patients from80
high volume sites, is being awaited.11 The objective of the
present study was to assess the performance of the Endurant
endograft device in patients with “friendly” and “hostile”
infrarenal abdominal aortic aneurysm (AAA) anatomical char-
acteristics.
METHODS
Study design-eligibility of patients. All patients with
nonruptured infrarenal AAA having undergone endovascu-
lar repair with the newly released Endurant endograft de-
vice at two vascular institutions during a period between
February 2009 and March 2010 were prospectively en-
rolled in the study. After initial CT assessment, patients
were recruited either to group I (GI) (n 43) or to group
II (GII, n  34) according to “friendly” or “hostile”
infrarenal aortoiliac axis anatomical characteristics, respec-
tively. Selection of the Endurant stent graft system among
other endografts was based on patient anatomy and on
physician preference. No funding from the device manufac-
turer was obtained.
The following general inclusion criteria were applied:
(1) the standard aneurysm criteria for EVAR; (2) patient
ability to provide informed written consent and willingness
to comply with follow-up schedule; (3) absence of concom-
itant disease (eg, terminal cancer), or other medical condi-
tion which would likely result in death, within 6 months of
implantation; (4) patient age 65 years and anatomical
suitability; and (5) patient age 65 years with incorpora-
tion of patient preference (informed consent selecting
EVAR instead of open AAA repair in healthy individuals,
where morphologic suitability existed). Hostile GII profile
necessitated any (or combination) of the following criteria:
5 mm  proximal neck length (Lpr) 12 mm, 60° 
proximal neck angle (Aopr) 90° and 60°  any iliac axis
angle (Aoiliac) 90°. The specific anatomical inclusion
criteria for patient allocation to each group and anatomical
definitions are presented in Table I.
Morphologic parameters, including atheroma or exten-
sive thrombus (2 mm thick)50% of cross-sectional area
lining the proximal neck up to the level of the lowermost
renal artery and severe (80%) infrarenal neck circumfer-
ential calcification precluded an endovascular option. Fur-
thermore, adverse neck morphology, including focal ex-
pansion of the proximal neck of at least 3 mm, within the
distance from the lowermost renal artery up to the first
infrarenal 15mm (bulging neck) and also gradual dilatation
of at least 2 mm of the proximal neck within its first
infrarenal 10mm (tapered neck) were not considered per se gontraindications for EVAR. Based on available sizes for
he proximal and iliac component, patients with proximal
eck diameter (Dpr) 19 mm  Dpr 32 mm and iliac
rtery diameter 8 to 25 mm were included in both groups.
n iliac artery distal fixation length 15 mm was required
or the endograft legs (Supplementary Table I, online
nly). Reporting standards for endovascular aortic aneu-
ysm repair and comorbidity status were used.12,22
End points and statistical analysis. Continuous data
re presented as means  standard deviation (SD). Cate-
orical data are given as counts (percentages) and absolute
alues. Observed baseline variables in the two patient
roups were compared. Differences between the groups
ere tested for statistical significance using the indepen-
ent t test (or the nonparametricMann-WhitneyU test) for
ontinuous variables, and the Pearson 2 test or Fisher
xact test for categorical variables as appropriate. Technical
uccess was defined as successful endograft deployment in
he intended proximal and distal anatomical position with-
ut evidence of type I or III endoleak, limb occlusion,
nd/or hemodynamically significant luminal stenosis on
ompletion angiogram, without the need for any secondary
nplanned surgical or endovascular interventions within
he first 24 hours. Clinical success was considered when no
neurysm expansion 5 mm, type I/III endoleak, aneu-
ysm rupture, conversion to open surgery graft migration,
r graft occlusion occurred within 6 months and 12
onths of endovascular treatment. Estimates of cumulative
vent rates were calculated by the Kaplan-Meier method.
ata were analyzed using the Statistica software (version
.0; STATSOFT, Tulsa, Okla) with differences being as-
umed significant at the level of P  .5.
ESULTS
Patient and AAA characteristics. Baseline demo-
able I. Anatomical abdominal aortic aneurysm (AAA)
nclusion criteria
ariable
For inclusion
in group I
(friendly)
For inclusion in
group II
(hostile)
roximal neck length
(Lpr)
Lpr 12 mm 5 mm  Lpr 
12 mm
roximal neck angulation
(A0pr)
A0pr  60° 60°  A0pr 
90°
liac artery angulation (in
either or both sides,
A0iliac)
A0iliac  60° 60°  A0iliac
90°
0pr is the angle created by the aortic midline running between the distal
nd of proximal neck and the aortic bifurcation and the midline running
rom the caudal renal artery to the distal end of the proximal neck.
0iliac is the most acute angle created by the midlines at any level between
he aortic bifurcation and common femoral artery.
pr was defined as the longitudinal distance between the first transverse CT
ection just distal to the lowermost renal artery and the first aneurysmal
15% outer aortic wall diameter vs diameter at the level of caudal renal
rtery) transverse CT section.raphics and clinical characteristics of the study groups are
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was basically performed using the Society for Vascular
Surgery/American Association for Vascular Surgery (SVS/
AAVS) medical comorbidity grading system,12 which re-
vealed a significant difference between the two groups (P
.036). AAA baseline anatomical characteristics and compar-
isons between the study groups are listed in Table III.
Proximal neck configuration and circumferential character-
istics (thrombus or calcifications) were not statistically dif-
ferent between the groups (Supplementary Table II, online
only). Figure 1 presents the neck shape distribution in the
study groups. In GII, the infrarenal aortic neck was shorter
than 10 mm in seven patients (20.6%), whereas the infra-
renal neck angulation was 70° in 13 patients (38.2%).
Technical aspects and early outcome. GI patients
were more likely to have local anesthesia (35.8% vs 14.7%,
P  .041). Procedure and radiation time were significantly
longer in group II (P  .037 and P  .001, respectively).
Implantation of the Endurant bifurcated device was suc-
Table II. Patient demographic data
Variable Group I (n 
Age (mean  SD), range 70.2 
Male gender 43 (1
ASA physical status classification
 III 14 (3
Unfit for open AAA repair/general
anesthesia
35 (8
Previous vascular operation 1 (2
Hypertension 34 (7
Diabetes 2 (4
Coronary diseasea 10 (2
Previous cardiac revascularization (PTCA
or/and CABG)
9 (2
Renal insufficiency 11 (2
1.1  pr-crt  2.4mg/dL 9
2.5  pr-crt  5.9mg/dL 2
COPD 5 (1
Cerebrovascular accident 1 (2
Smoking history
Current smoker 12 (2
Previous smoker 9 (2
Hypercholesterolemia 11 (2
Obesity (BMI 30 kg/m2) 14 (3
Peripheral vascular disease 2 (4
Previous nonvascular abdominal operation 2 (4
Previous abdominal endovascular procedure 1 (2
Arrhythmia 2 (4
Preoperative platelets, mean  SD (range) 213,071  80,048
Mean SVS/AAVS score (range)12 (3-point
scale)c
0.5  0.4 (0.1
Presence of inguinal or umbilical hernia 9 (2
AAA, Abdominal aortic aneurysm; ASA, American Society of Anesthesiol
chronic obstructive pulmonary disease; pr-crt, preoperative creatinine; PT
Vascular Surgery/American Association for Vascular Surgery.
aCoronary disease defined as having a history of any of the following:
revascularization (percutaneous or surgical), angina, or cardiac valvular dise
bUse of Mann–Whitney U test in case of nonsymmetric distribution of data
cA general approach for categorization and weighting of disease severity in wcessfully employed in all but two patients, in whom an aortouniiliac device was used because of accidental con-
ralateral stump opening into the common iliac artery
CIA). Technical success in GI and GII was achieved in
5.4% and 100%, respectively (P  .88). Aortouniiliac
evices were successfully implanted in two patients with
hronic occlusion of the contralateral iliac axis. A 10 mm
olytetrafluoroethylene (PTFE) iliac conduit was required
or stent graft introduction in one of these patients. Re-
lignment of a tube Endofit endograft with a 36-mm
roximal diameter bifurcated Endurant device was per-
ormed in one patient to treat to a type Ib endoleak
esulting in an enlarging aneurysm. The cross-limb tech-
ique was more often required in GII (P  .013). No
ignificant differences in the patients requiring iliac exten-
ions were identified (28 patients in GI vs 23 in GII, P 
916). However, bilateral iliac extensions were most com-
only required in GII (16 vs 9, P  .073). Twenty-four
atients had concomitant CIA aneurysm(s), which were
ilateral and of type D or E morphology in 11 patients,
Number (%)
P value55.8%) Group II (n  34, 44.2%)
72.8  7.3 .106
33 (97.1) .927
19 (55.9) .197
30 (88.3) .812
1 (2.9) .87
26 (79.5) .923
5 (14.7) .166
14 (41.2) .225
5 (14.7) .557
19 (55.9) .075
16
3
8 (23.5) .245
5 (14.7) .064
13 (38.2) .494
9 (26.5) .654
9 (26.5) .946
13 (38.2) .72
5 (14.7) .166
7 (20.1) .056
1 (2.9) .87
4 (11.8) .286
00-502,000) 214,526  53,845 (131,000-341,000) .945
0.8  0.6 (0.1-2.5) .036b
8 (23.5) .823
BMI, body mass index; CABG, coronary artery bypass grafting; COPD,
percutaneous transluminal coronary angioplasty; SVS/AAVS, Society for
hmia, myocardial infarction, congestive heart failure, previous coronary
the 0 to 3 scale corresponds to absent, mild, moderate, and severe disease.43,
5.9
00)
2.6)
1.4)
.3)
9.1)
.7)
3.3)
0.9)
5.6)
1.6)
.3)
7.9)
0.9)
5.6)
2.6)
.7)
.7)
.3)
.7)
(48,0
-1.8)
0.9)
ogists;
CA,
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Repair) criteria.23 Internal iliac artery (IIA) aneurysms were
present in five patients and were left intact in two of them
Table III. AAA anatomical characteristics
Variable
AAA diameter (mean  SD in mm) [range] 58
Proximal neck diameter (mean  SD in mm) [range]
 21 mm
22-25 mm
26-28 mm
29-32 mm
Proximal neck length (mean  SD in mm) [range] 19
 25 mm
16-25 mm
11-15 mm
 10 mm
Proximal neck angulation (mean  SD in mm) [range] 18
 45°
45°-60°
61°-70°
 70°
Type of proximal neck
I (cylindrical)
II (conical)
III (reverse conical)
IV (barrel)
V (hourglass)
Left iliac artery angulation (°), mean  SD, [range] 146
Right iliac artery angulation (°), mean  SD, [range] 147
AAA, Abdominal aortic aneurysm; NA, not applicable.
aAll 12 mm.
bMann-Whitney U test was used for continuous variables in case of nonsym
Fig 1. Neck morphology distribution in the study groups.(diameter 22 mm). Further intraoperative details are tiven in Table IV (see also Supplementary Table III, online
nly).
Occlusion of the IIA was performed in 21 cases (20
ntentionally and one accidentally), with a significant differ-
nce between the two groups (GI vs GII, 21.5 vs 7.2%; P
028). Intentional occlusion of the hypogastric artery was
erformed either to exclude a CIA (or CIA  IIA) aneu-
ysm or to treat a type Ib endoleak in the majority of cases.
hree type Ia (all GII patients, P  .057), 7 type Ib (3 GI
nd 4 GII patients, P .509) and 4 type II endoleaks were
dentified on completion angiogram. Patients who experi-
nced intraoperative type Ia endoleaks had proximal neck
ength, angulation, and quality of 15 mm/20 mm/9 mm,
4°/82°/73° and reverse conical/cylindrical/cylindrical,
espectively. In two of them the endoleak was successfully
anaged with aortic cuff deployment. In the remaining
ase, balloon angioplasty at proximal anchor zone success-
ully sealed the endoleak. Interestingly, when patients with
liac angulation criteria only (5/34) were taken out of GII,
ype Ia endoleak was significantly higher in GII (P  .04).
One GI patient with a large inflammatory aortoiliac
neurysm was admitted to the intensive care unit 5 days
fter the EVAR procedure due to hemodynamic instability.
low postoperative Hb was investigated with a CT and an
ngiogram, revealing that the aneurysm was fully excluded
rom the circulation without evidence of any type of en-
oleak. No other source of bleeding was identified. Unfor-
Number (%)
P valueGroup I Group II
8.6 [45-80] 60.4  13 [40-100] .842b
3.8 [20-32] 26.6  3.8 [20-32] .485
1 (25.6) 3 (8.8) .111
7 (16.3) 13 (38.2) .097
2 (27.9) 6 (17.6) .403
3 (30.2) 12 (35.3) .737
4.5 [13-35] 18.1  9.1 [8-48] .161b
3 (7) 5 (14.7) .322
8 (65.1) 12 (35.3) .137
2 (27.9)a 10 (29.4) .914
NA 7 (20.6)
17 [0°-52°] 62  21.6 [0°-84°] .001
9 (90.7) 4 (11.8) .001
4 (9.3) 5 (14.7) .516
NA 12 (35.3)
NA 13 (38.2)
1 (72.1) 21 (61.8) .671
8 (18.6) 10 (29.4) .382
2 (4.7) 2 (5.9) .819
1 (2.3) 1 (2.9) .87
1 (2.3) 0 .386
24.6 [94°-178°] 113.3  45.8 [45°-180°] .001
28 [92°-180°] 107.2  48.3 [10°-180°] .001b
distribution of data..7 
26 
1
1
1
.7 
2
1
.2 
3
3
.8 
.8 unately, the patient died of multiorgan failure on the 15th
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Variable
Number (%)
P valueGroup I Group II
Anesthetic option
General 2 (4.7) 3 (8.8) .49
Spinal 23 (53.5) 25 (73.5) .388
Epidural  spinal 0 1 (2.9) .265
Local 19 (35.8) 5 (14.7) .041
Procedure duration in minutes, mean  SD (range) 80.5  39.8 [25-180] 102.4  51.2 [37-240] .037
Radiation time in meanutes, min  SD (range) 19.9  10.1 [9-52] 32.5  12.1 [10-50] .001
Endograft configuration, sizes, fixation
Bifurcated 40 (93) 33 (97.1) .897
Aortouniiliac 3 (7) 1 (2.9) .451
Proximal diameter, mean  SD, range 30.5  4.3 [25-36] 30.4  4.3 [25-36] .962
Distal fixation sites (DFS)a 37/80 (42.5), 36/80 (45) 25/66 (37.9), 28/66 (42.4) .516/.845
RCIA, LCIA 3/80 (3.8), 4/80 (5) 9/66 (13.6), 4/66 (6.1) .047/.791
REIA, LEIA 37/83 (44.6) 39/67 (58.2) .344
Iliac axis sites requiring extension(s)
Bileteral extensions (per total sites)
9/83 (10.8) 16/67 (23.9) .073
Total implanted endograft parts, mean  SD (range) 120, 2.86  0.77 (2-4) 104, 3.29  1.06 (2-5) .258c
Requirement for troubleshooting techniques 0 7 (20.6) .0047
Intraoperative complications
Acute conversion to open repair 0 0 NA
Failed deployment 0 0 NA
Endograft misplacement (short limb opened at CIA) 2 (4.7) 0 .213
Partial occlusion of renal artery ( 50%) 0 1 (2.9) .265
Perforated EIA 1 (2.3) 0 .376
Open femoral artery repair 1 (2.3) 0 .376
Allergic reaction 1 (2.3) 0 .376
Intraoperative adjunctive procedures
(intentional/accidental or unplanned)
Conversion to AUI and Fem-Fem bypass 2 (4.7) 0 .213
Cross-limb technique 1/40a (2.5) 8/33a (24.2) .013
CIA or EIA angioplasty for delivery system passage 4 (9.3) 2 (5.9) .606
CIA stent insertion 1 (2.3) 2 (5.9) .442
Total intentional/accidental occlusion of IIA 6/83 (7.2) 14/65 (21.5) .028
IIA aneurysm embolization 1 (2.3) 2 (5.9) .442
Proximal neck balloon angioplasty (Reliant®) 41 (95.3) 31 (91.2) .892
Distal endograft parts balloon angioplasty
(Reliant®)
43 (100) 34 (100) 1
Proximal aortic cuff deployment for type Ia EL 0 2 (5.9) .118
Proximal aortic neck ballooning for type Ia EL 0 1 (2.9) .265
Reasons for distal limb extensions deployment
CIA aneurysm exclusion 4/83 sites (2.7) 9/67 sites (13.4) .089
Inadequate distal non-aneurysmal iliac fixation
length
30/83 sites (36.2) 24/67 sites (35.8) .978
Type Ib EL 3/83 sites (3.6) 4/67 sites (6) .517
EL at completion angiogram
Type Ia 0 3 (8.8) [10.7]b .057 [.037]b
Type Ib 3 (7) 4 (11.8) .509
Type II 3 (7) 1 (2.9) .451
Technical success (extended through the first 24
hours)
41/43 (95.4) 34/34 (100) .88
Endograft limb thrombosis 24 hours 1 (2.3) 0 .376
Postoperative fever (unknown origin)d 9 (20.9) 19 (61.8) .032
Aneurysm-related mortality (30 days) 1 (2.3) 0 .376
Operative deaths (30 days) 2 (4.7) 0 .213
Hospitalization dates, mean (range) 4.7  2.1 (3-15) 4.2  3 (2-19) .15c
AUI, Aortouniiliac; CIA, common iliac artery; EIA, external iliac artery; EL, endoleak; EVAR, endovascular abdominal aortic aneurysm repair; fem-fem,
femoral-femoral cross-over bypass; IIA, internal iliac artery; L, left; MSOF, multiple system organ failure; NA, not applicable; R, right; SD, standard
deviation.
aAUI cases excluded (83 DFS for group I, 66 DFS for group II).
bWhen patients with only iliac angulation criterion (6/34) were dropped out from GII.
cMann-Whitney U test was used for continuous variables in case of nonsymmetric distribution of data.
dTemperature 38° C 1 onsets for at least 2 days.
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creatinine level) requiringmultiple dialysis sessions and also
pulmonary complications are presumed to have precipi-
tated the multiorgan failure (1.3%, P  .376). Another GI
patient died of a myocardial infarction on post-EVAR day
24 (total 30-day mortality 2.6%). Mean hospital stay for the
remaining patients was 4.7  2.1 days (range: 3-15) and
4.24 2.97 days (range: 2-19) for GI and GII, respectively
(P  .021). Postoperative fever of unknown origin (post-
implantation syndrome [PIS]) was observed in 28 (36.4%)
patients (GI  9, GII  19, P  .032) with a mean
duration of 2.02 days (range: 0-8 days). Other EVAR
details of both groups are listed in Table IV (see also
Supplementary Table III, online only).
Table V summarizes the anatomical features of the
proximal neck and the outcomes related to specific very
hostile GII subgroups. When compared with GI, GII sub-
groups with severe Ao 70° or featuring other than cylin-
drical neck shape, had significantly higher chance for any
type of endoleak (P  .012).
Clinical outcome on follow-up. Three GII patients
(3/75) died during the follow-up period due to reasons
unrelated to the aneurysm (myocardial infarction in two
patients and hepatic cancer in another, late mortality rate
3.9%). Complete thrombotic endograft limb occlusion oc-
curred in four patients of GI (6 months in three, one in
the early postoperative period), which was managed with a
femoral-femoral cross over PTFE bypass. All remaining
Endurant limbs (n  137) remained patent (137/141,
97.2%) with no stent fractures or migrations. Maximum
aneurysm diameter was reduced in 52 patients (52/72,
69.3%) and remained unchanged in 23 (30.7%). One out of
Table V. Anatomical features of the proximal neck and th
Hostile proximal neck feature (GII
subgroups)
No of patients
affected (%)
Wide diameter (28-32 mm)b 13 (38.2) 30
Angulation (Ao)  60° 25 (73.5) 71
60°  angulation  70° 12 (35.3) 66
71°  angulation  90° 13 (38.2) 76
Not cylindrical 13 (38.2)
Length (L)  12 mm
Short-length (5-12 mm) 14 (41.2) 10
Neck length 10 mm (outside IFU) 7 (20.6) 8
L  12 mm and Ao  60° 10 (29.4)
L  12 mm and Ao  70° 6 (17.7)
L 5-9 mm and Ao  60° 4 (11.8)
All patients except AUI cases 32 (94.1)
All patients except purely iliac angulated
cases
29 (85.3) 26
6
16
AUI, Aortouniiliac; EL, endoleak; GI, group I; GII, group II; IFU, instructi
SD, standard deviation.
aLog rank test.
bRefers to the widest part of the neck.
cGI also without AUI cases.
d, e, fRefer to proximal neck diameter, angulation, and length, respectively.the four type II endoleaks which were identified on-table cesolved within 1 month. In the remaining three persisting
ype II endoleaks, no enlargement of the aneurysm sac was
vident up to the latest follow-up. No type I/III endoleaks
r migrations were recorded during follow-up. Freedom
rom any type of endoleak at 12 months was 93.2% for GI,
nd 86% for GII (P  .21, Fig 2). Freedom from any early
r late intervention at 12 months was 87.1% for GI and
3.4% for GII (P  .066, Fig 3). Freedom from aneurysm
elated death was 93.3% and 93.4% at 12 months for GI
nd GII, respectively. Clinical success was 92.7% (38/41)
nd 100% (31/31) within 6 months and 82.1% (23/28)
nd 100% (22/22) within 12 months for GI and GII,
espectively (P6mo  .961 and P12mo  .633). Further
ollow-up details are given in Table VI.
ISCUSSION
In the last decade, EVAR has evolved as an effective
nnovative treatment option for AAA disease. Selection of
n appropriate stent graft size and design is one of the
ritical components for successful positioning and subse-
uent exclusion and depressurization of the aneurysm
ac.24 Furthermore, stringent morphologic criteria have
een used to select patients for EVAR and have been found
o be of importance to achieve durable results.9,12,25 The
ver expanding use of EVAR and the fact that a significant
roportion of patients with hostile aneurysm anatomy re-
eive endovascular treatment,3,19,20,26-28 emphasizes the
eed for advanced endograft devices.
This prospective study was conducted to compare per-
ormances of the newly released Endurant endograft be-
ween patients with “friendly” and “hostile” infrarenal
ortic anatomy. Early results of the largest ongoing multi-
comes related to specific very hostile GII subgroups
 SD
Outcome
Any type of EL/secondary
intervention (%)
P (GII subgroup vs
GI)a
1.09 1 (2.9)/0 .384/.276
6.46 3 (8.8)/0 .127/.133
3.06 0/0 NA / NA
4.28 3 (8.8)/0 .012/.259
A 3 (8.8)/0 .012/.244
1.71 0/0 NA/.234
0.54 0/0 NA/.405
A 0/0 NA/NA
A 0/0 NA/NA
A 0/0 NA/NA
A 3 (8.8)/0 .218c/.063c
3.74d 3 (8.8)/0 .153/.09
16.41e
7.74f
r use;NA, not applicable (less than two censored cases to perform analysis);e out
Mean
.77 
.84 
.42 
.84 
N
.07 
.43 
N
N
N
N
.83 
7.1 
.69 
ons foenter prospective study on the Endurant device (Endurant
p
7
w
d
a
f
E
p
c
(
6
h
B
u
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September 2011622 Georgiadis et alStent Graft Natural Selection Global Postmarket Registry
[ENGAGE]) are promising.11 Furthermore, several studies
have reported on the short- and midterm EVAR outcome
with the Endurant device.8,9,19 In accordance with the
ENGAGE registry, we expanded the inclusion criteria ap-
plied for EVAR (GII), to examine and compare the safety
and efficacy of the Endurant stent graft in two anatomically
different patient populations. An interim analysis of the first
180 ENGAGE EVAR cases revealed that only 13.4% and
10.6% of patients had proximal neck length 15 mm and
angulation 60°, respectively.11 Torsello et al8 and Troisi
et al9 in their cohort of 45 and 156 patients, respectively,
treated with the Endurant stent graft, short (10 mm)
and/or angulated (60°) proximal neck was present in
31% and 58%, and in 29.5% and 39.1% of their patients,
0 3 6 9
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
1,1
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Log-Rank test = .21
GROUP I Time (months) 
Freedom from any 
type of endoleak 
N at risk 
Cumulative 
proportion surviving
SE 
GROUP II Time (months) 
Freedom from any 
type of endoleak 
N at risk 
Cumulative 
proportion surviving
SE 
Fig 2. Estimate of freedorespectively. In our study, half of the patients in GII had troximal neck length15 mm (20.6% with10 mm) and
3.5% had proximal neck angulation 60° (38.2%
ith 70°), suggesting even more hostile anatomical con-
itions. The presence of a short proximal10 mm and/or
ngulated60° neck represents an independent risk factor
or periprocedural and late complications following
VAR.13,14,17,28,29 However, our cut-off values regarding
roximal hostile neck (Lpr  5 mm, Aopr  90°) do not
orrespond to the limits set by the instructions for use
IFU) for this endograft model (Lpr 10 mm and Aopr
0° or as of 75° where Lpr  15 mm). Angulations as
igh as 90° have also been set by Torsello et al,8 whereas
astos-Concalves et al19 have featured infrarenal angles of
p to 125° (mean Aopr  80.8°).
In the first 80 patients enrolled in a European pivotal
15 18 21 24
ths
Group I
Group II
0 3 6 9 12 15 
43 41 40 28 24 17 
100 98.8 96.4 95 93.2 90.9 
0 1.7 2.9 3.5 4.3 5.2 
0 3 6 9 12 15 
34 31 29 24 20 7 
100 91.2 89.7 88 86 82.8 
0 4.9 5.2 5.7 6.2 7.4 
m any type of endoleak.12
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Volume 54, Number 3 Georgiadis et al 62330-day freedom from all cause mortality was noted in
97.5%, and the technical success rate was 91% when three
periprocedural endoleaks (type I  1, type III  2), one
graft thrombosis, and three secondary endovascular inter-
ventions were considered.11 Further analysis found compa-
rable results between subgroups of patients recruited based
on the infrarenal angulation (60° and 60-75°).10,11 An
interim analysis of the first 180 patients of the ENGAGE
study revealed a successful stent graft deployment in 99.4%
of the cases and an all causemortality rate of 1.7%. Only one
type I endoleak was observed, whereas no type III en-
doleaks, stent graft kinking or graft thrombosis/occlusion
were reported; one conversion to open repair and two
secondary endovascular procedures were undertaken.11
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Log-Rank test = .066
GROUP I Time (months) 
Freedom from early or 
late intervention 
N at risk 
Cumulative proporti
surviving 
SE 
GROUP II Time (months) 
Freedom from early or 
late intervention 
N at risk 
Cumulative proporti
surviving 
SE 
Fig 3. Estimate of freedomThe technical and clinical success rates reported in our ctudy were similar to those of the above trials, and interest-
ngly, did not differ significantly between the two groups.
The Endurant device has also been previously been
ssessed in studies where stricken or expanded selection
riteria for EVARwere applied.8,9 Torsello et al8 in a cohort
f 45 patients treated with the Endurant device, 38 (84%)
f whom had hostile proximal neck anatomy, reported
reedom from type I/III endoleak and repeat intervention
f 97.8% and 93.3% at 1 year, respectively. In that study,
ne type I endoleak and one limb thrombosis occurred
ithin the early postoperative period yielding technical and
linical success rates of 97.8% and 95.6%, respectively.8 In a
imilar population with complex AAA proximal neck anat-
my, Troisi et al9 reported 30-day overall technical and
15 18 21 24
ths
Group I
Group II
0 3 6 9 12 15 
43 38 38 27 23 16 
100 92.9 91.6 88.9 87.1 84.8 
0 4 4.3 5 5.5 6.2 
0 3 6 9 12 15 
34 34 32 26 22 9 
100 98.5 97 95.4 93.4 90.4 
0 2.1 2.9 3.7 4.6 6.1 
early or late interventions.12
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September 2011624 Georgiadis et almean follow-up period of 9 months, the estimated survival,
freedom from type II/III endoleak, freedom from graft
thrombosis, and freedom from any device-related reinter-
ventions at 2 years were noted in 94.7%, 96.9%, 97.8%, and
92.6% of the patients, respectively.9 In our study, the mean
follow-up periods of the two groups (GI  12.9 months,
GII 12.4 months) were longer, with 58.1% and 64.7% of
the patients having attended the 12-month follow-up ap-
pointments. No significant differences in the primary out-
comes between the two groups were observed, suggesting
similar performances of the Endurant device in favorable
and adverse aneurysm morphologies. This finding is con-
sistent with the early results of the ENGAGE registry.11 No
secondary I/III endoleaks were noted in either study
group, which underlines the good sealing capacity of the
stent graft and represents the good short- and midterm
results. Secondary interventions were required in three
patients of GI to treat limb endograft thrombosis (7%),
which is consistent with a recent analysis of predictors for
graft limb occlusion citing a 7.2% event rate,30 but higher
than the 1.3% of limb thrombosis presented in a recent
large study with implantation of the Endurant endograft.9
Notably, two of these patients required endograft exten-
sion to the external iliac artery was required, which is a
known predisposing factor for limb occlusion.
The technical efficacy of the Endurant device in the
present study, represented by the technical success rates, is
comparable with that of other contemporary commercial
devices applied in less favorable neck anatomies, for exam-
ple, the Aorfix (Lombard Medical Technologies, Didcot,
Table VI. EVAR follow-up results
Variable
Completed follow-up
6 months
12 months
Mean follow-up SD (range) 12.9
Late endoleak (1 month)
II (side branch)
Device migration (10 mm)
AAA diameter
Stable
Reduced
Expanded 5mm
Aneurysm but not device-related death (1 month)
Death unrelated to aneurysm
AAA rupture
Late conversion to open repair
Secondary interventions fem-fem PTFE bypass
Clinical success
Through 6 months
Through 12 months
Death on follow-up (other than aneurysm related)
EVAR, Endovascular abdominal aortic aneurysm repair; fem-fem, femoral-fe
standard deviation.
aExcluding two early (30 days) deaths.
bExcluding three deaths unrelated to AAA.United Kingdom) and the Anaconda (Vascutek, Terumo, lnchinnan, Scotland) graft systems have been reported to
e associated with success rates of 95%3 and 100%,5 respec-
ively, in studies, including patients with severe neck angu-
ation (35% with 61-70° or 25% with 70o3 and 39% with
60o5, respectively). A recent report evaluating 30 patients
ith angulated anatomies (all with neck angle 60°, in-
luding 63% with neck angle75°) treated with the Aorfix
tent graft, achieved lower clinical success (92.6%) within
he first 6 months after the operation, with two recurrent
ype Ia endoleaks being reported.20
Moderate (40%-59%) to severe (60%) angulation of
he proximal aneurysm neck has been demonstrated to be
ssociated with acute or late adverse events following
VAR despite an adequate proximal aortic length (20
m) and, probably, regardless of the type of the endograft
sed.14 Furthermore, previous reports have shown that
ndovascular treatment of aneurysms with an angulated
eck 60° is commonly associated with adjunctive proce-
ures, such as giant Palmaz (Cordis, Miami Lakes, Fla)
tent or cuff placement to achieve proximal seal.28,31 In our
ohort, all three type I endoleaks found on completion
ngiogram were successfully treated with either cuff place-
ent or balloon dilatation of the proximal aortic neck. Low
r zero frequencies of intraoperative or 30-day type I
ndoleaks have previously been reported (0%-2.2%)8,9,11,19
ith the Endurant device, which may be attributable to the
roximal stent design with the penetrating hooks and tip-
apture delivery system promoting more active suprarenal
xation and enhanced proximal positioning.11,19 Bastos-
oncalves et al19 looked at 45 and 65 patients with angu-
Number (%)
P valueroup I Group II
41 (95.3) 31 (91.2) .892
25 (58.1) 22 (64.7) .773
.94 (6.4-19.8) 12.44  4.02 (4.2-19.6) .62
3 (7) 0 .13
0 0 NA
1a (31.7) 10/34 (29.4) .876
1a (68.3) 24/34 (70.6) .927
0 0 NA
1 (2.3) 0 .376
3 (7) 1 (2.9) .451
0 0 NA
0 0 NA
3 (7) 0 .13
1a (92.7) 31/31b (100) .961
8a (82.1) 22/22b (100) .633
0 3 (8.8) .057
cross-over bypass;NA, not applicable; PTFE, polytetrafluoroethylene; SD,G
2  3
13/4
28/4
38/4
23/2
moralated and nonangulated proximal neck, respectively, and
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Volume 54, Number 3 Georgiadis et al 625found that the average distance from the lowermost renal
artery to the covered part of the stent graft on the first
postoperative computed tomography angiography was not
statistically different between the two groups, suggesting
that suprarenal active fixation and the tip-capture delivery
system enable optimal transrenal positioning of the device,
which is a better choice especially in short necks.
Interestingly, the incidence of loss of proximal sealing
length has been reported to be higher (6.7%) with the
Aorfix stent graft.20 The higher incidence of type I en-
doleak in our cohort might be explained by the severe
proximal neck angulation (all patients with type I endoleak
had severely angulated infrarenal neck, 84°/82°/73°) since
no loss of distance from renal to graft was observed. Nota-
bly, the incidence of type Ia endoleak was 33% (2/6) in the
subgroup of patients with80° proximal neck angulation.
Proximal endograft fixation especially in angulated
necks might be augmented by several mechanical means,
including radial force, suprarenal fixation, or penetrating
hooks and barbs. Use of suprarenal fixation, as in the
Endurant device, serves as an option for treating complex
proximal neck anatomy and increases the positional stability
of the endograft based on the principles of increased fixa-
tion length, including a less diseased segment of the aorta.
However, newer infrarenally oriented flexible endografts,
featuring proximal circumferential ring stent design and
hooks, achieve greater radial force, providing also satisfac-
tory proximal seal.3,5,6,16 Recent data confirm that even
deploying solely suprarenal devices, intraoperative adjunc-
tive interventions remain more frequent in severely angu-
lated necks,28 whereas other clinical studies have demon-
strated that suprarenal aortic attachment is associated with
reduced risk of proximal endoleaks.29,32 Technical factors
of the Endurant device, such as the wire-formed M-shaped
bare laser-cut nitinol stents, the anchoring pins at proximal
stent, and the controlled release of the top stent, are pre-
sumed to achieve accurate deployment and produce com-
plete proximal sealing.
Deviation from other anatomical proximal neck guide-
lines for successful EVAR may also affect the outcome.
Stanley et al26 found four combinations of EVAR indica-
tion creeps related to proximal aneurysm neck, strongly
associated with endoleak; contour change (3 mm)-large
diameter (28 mm), contour change-short-length (20
mm), large diameter-short-length and contour change-
angle (30°) are those combinations associated with early
or late type I endoleak. Mohan et al33 demonstrated that
short and wide proximal necks are strongly correlated with
an increasing incidence of proximal endoleak. However, in
other studies, the presence of wide necks,28 or the presence
of angulated (60°)29 or in general hostile necks13 has not
been linked with increased chance of early or late proximal
type I endoleak or increased incidence of periprocedural or
late complications, respectively. In our study, severe prox-
imal neck angulation (70°) or other adverse anatomical
features of the proximal neck (not cylindrical) had signifi-
cant impact on the incidence of endoleak (Table V). sOur study has also confirmed the suggested association
etween the clinical status of the patients and the anatom-
cal complexity of lesions of their AAAs since the mean
VS/AAVS was found to be significantly higher in the
ostile GII (high clinical risk links to high morphologic
isk).8,9,15,19 Both groups had also high percentage of
atients deemed unfit for open repair and/or general anes-
hesia. Even American Society of Anesthesiologists (ASA)
I patients with aortoiliac aneurysms (AAA of type C and D
r E), smoking history, obesity, and previous abdominal
perations were included in this category. Literature evi-
ence confirms that patients with adverse aneurysm anat-
my have higher prevalence of ASA  III scores, ranging
etween 45% and 84.7%.3,7-9,19,20 Corresponding percent-
ges for patients unfit for open repair or general anesthesia,
ange between 55% and 73.3%.3,19
Combined severe comorbidity and anatomical adversi-
ies in GII patients might also explain the reduced likeli-
ood of receiving local anesthesia techniques. Recent re-
orts suggest a strategy based on the preferential use of
ocal anesthesia for EVAR, restricting regional anesthesia or
eneral anesthesia only to those with predefined contrain-
ications.34 However, the shorter expected procedure time
n favorable anatomy and the expected requirement for
ore operating time and troubleshooting techniques in
ore challenging anatomy, influenced our practice toward
he preferential use of local and spinal anesthesia in GI and
II, respectively. Furthermore, unfavorable infrarenal
orta and iliac anatomy are possibly responsible for the
ignificantly increased duration of the procedure and radi-
tion time in GII patients.
Of interest in our study is the increased requirement of
roubleshooting techniques and the utilization of the cross-
imb technique in GII patients. These technical issues
ight be attributed to the higher morphologic risk and
urved anatomy in this group. Technical expertise required
n hostile anatomy suggests that the threshold of only three
uccessful implantations11 is not the optimal learning curve
ith the Endurant device. To obtain an adequate seal at the
liac level or to resolve a type Ib endoleak, deployment of at
east 1 iliac extension was necessary in 66.2% of patients
GI  44.6%, GII  58.2%). This figure is close to that
eported by Torsello et al (60%)8 and Troisi et al (47%)9
mplanting the same device. Although not routine practice
n our study, placement of iliac extenders modules to
xtend the stent graft to the level of the hypogastric artery
ontributes to its proximal stability independent on the
uprarenal or infrarenal stent graft design.35 Although mi-
ration of an infrarenal endograft with longitudinal colum-
ar support has been reported to be as closely related to the
dequacy of iliac fixation,35 the role of iliac fixation length
n suprarenal devices adopting penetrating hooks like the
ndurant device remains to be determined, especially when
roximal fixation length is suboptimal. In contrast to pre-
ious reports, iliac limb stenosis requiring angioplasty
nd/or stenting was not frequently encountered in our
eries. A small proportion of our patients (2.6%) required
tenting of such stenoses, which is lower than the reported
11
1
1
1
1
1
1
1
1
2
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September 2011626 Georgiadis et alfigures of 11% to 12.2% of other studies,8,9 but very close to
the incidence of 0.6% in the ENGAGE registry.11 The
higher percentage of patients with AAAs of type D or E in
GII, increased the likelihood for intentional IIA occlusion
in this subpopulation.
PIS more frequently occurred in GII than GI patients
(61.8% vs 20.9%). All our patients with PIS developed fever
leukocytosis and increased C-reactive protein levels, but the
impact of this syndrome on the outcome of our patients was
negligible. Interestingly, we observed a similar percentage
of PIS in patients with implantation of the Talent
(Medtronic, Inc, Santa Rosa, Calif) device. In a recent
study 40% of Talent implantation patients experienced
PIS.36 The incidence in our series was much higher than
that reported by Torsello et al (16%), which might be
explained by the anatomical complexity and/or increased
comorbidities in the present cohort.
The overall early mortality rate (2/77 or 2.3%, 0% for
GII) in our study was similar to that in the EUROSTAR
registry (2.9%) the ENGAGE trial (1.7%) and a recent
multicenter Endurant study (2.7%, 2.2% in the angulated
group).19
CONCLUSIONS
The Endurant stent graft seems to be efficient and safe
for patients with adverse aneurysm anatomies. Friendly and
hostile groups had equal performances regarding technical
and clinical success and freedom from any type of endoleak,
early or late secondary interventions, and aneurysm related
death. However, more intra- and perioperative adversities
were encountered in the last group. Larger prospective
studies or even randomized trials comparing different new
generation graft models are required to evaluate the com-
parable long-term results and possible expansion of EVAR
indications for this specific endograft in adverse anatomies.
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section just distal to the lowermost renal artery and the first aneurysmal (15%
nsverse CT section.
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Variable
For
Proximal neck diameter (Dpr)
Proximal neck length (Lpr) Lp
Proximal neck angulation (A0 pr) A0
Proximal neck “bulge”
Tapered proximal neck
Proximal neck atheroma or thrombus
(2 mm thick) lining the proximal
neck up to the renal arteries
Proximal neck circumferential
calcifications
Iliac artery sealing zone diameter
Iliac artery angulation (in either or
both sides, A0 iliac)
A0
Distal iliac artery fixation length
A0 pr: the angle created by the aortic mid-line running between the distal en
caudal renal artery to the distal end of the proximal neck.
A0 iliac: the most acute angle created by the mid-lines at any level between
Lpr was defined as the longitudinal distance between the first transverse CT
outer aortic wall diameter vs diameter at the level of caudal renal artery) trainclusion in group I
(friendly)
For inclusion in group II
(hostile)
19 mm  Dpr  32 mm
r 12 mm 5 mm  Lpr  12 mm
pr  600 600  A0 pr  900
Present or not
Present or not
50% cross-sectional area
 80%
8-25 mm
iliac  600 600  A0 iliac  900
 15 mm
d of proximal neck and the aortic bifurcation and the mid-line running from the
the aortic bifurcation and common femoral artery.
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Variable
Number (%)
P valueGroup I Group II
AAA diameter (mean  SD in mm) [range] 58.7  8.6 [45-80] 60.4  13 [40-100] .842b
AAA Type23
A 19 (44.2) 10 (29.4) .368
B 14 (32.6) 9 (26.5) .67
C 9 (20.9) 3 (8.8) .21
D 1 (2.3) 8 (23.5) .01
E 0 4 (11.8) .03
Proximal neck diameter (mean  SD in mm) [range] 26  3.8 [20-32] 26.6  3.8 [20-32] .485
21 mm 11 (25.6) 3 (8.8) .111
22-25 mm 7 (16.3) 13 (38.2) .097
26-28 mm 12 (27.9) 6 (17.6) .403
29-32 mm 13 (30.2) 12 (35.3) .737
Proximal neck length (mean  SD in mm) [range] 19.7  4.5 [13-35] 18.1  9.1 [8-48] .161b
25 mm 3 (7) 5 (14.7) .322
16-25 mm 28 (65.1) 12 (35.3) .137
11-15 mm 12 (27.9)a 10 (29.4) .914
10 mm NA 7 (20.6)
Proximal neck angulation (mean  SD in mm) [range] 18.2  17 [0o-52o] 62  21.6 [0o-84o] .001
 45o 39 (90.7) 4 (11.8) .001
45o-60o 4 (9.3) 5 (14.7) .516
61o-70o NA 12 (35.3)
 70o NA 13 (38.2)
Renal artery stenosis (70%) or occlusion 2 (4.7) 7 (20.6) .056
Aortic neck calcification/thrombus
25% 34 (79.1) 26 (76.5) .923
25-50% 8 (18.6) 7 (20.6) .858
50% 1 (2.3) 1 (2.9) .87
Type of proximal neck
I (cylindrical) 31 (72.1) 21 (61.8) .671
II (conical) 8 (18.6) 10 (29.4) .382
III (reverse conical) 2 (4.7) 2 (5.9) .819
IV (barrel) 1 (2.3) 1 (2.9) .87
V (hourglass) 1 (2.3) 0 .386
Left iliac artery sealing zone diameter (mm), mean  SD,
[range]
15.3  6 [10-40] 17.6  9.1 [10-50] .38b
Right iliac artery sealing zone diameter (mm), mean  SD,
[range]
14.6  4.7 [10-37] 20.3  14.8 [0-78] .134b
Left iliac artery angulation (o), mean  SD, [range] 146.8  24.6 [94o-178o] 113.3  45.8 [45o-180o] .001
Right iliac artery angulation (o), mean  SD, [range] 147.8  28 [92o-180o] 107.2  48.3 [10o-180o] .001b
aAll 12mm
bMann-Whitney U test was used for continuous variables in case of nonsymmetric distribution of data.
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Variable
Number (%)
P valueGroup I Group II
Anesthetic option
General 2 (4.7) 3 (8.8) .49
Spinal 23 (53.5) 25 (73.5) .388
Epidural  spinal 0 1 (2.9) .265
Local 19 (35.8) 5 (14.7) .041
Procedure duration in min, mean  SD
(range)
80.5  39.8 [25-180] 102.4  51.2 [37-240] .037
Radiation time in min, mean  SD
(range)
19.9  10.1 [9-52] 32.5  12.1 [10-50] .001
Contrast volume in mL, mean  SD
(range)
163.3  47.2 [70-230] 198  50.4 [120-310] .053
Endograft configuration, sizes, fixation
Bifurcated 40 (93) 33 (97.1) .897
Aortouniiliac 3 (7) 1 (2.9) .451
Proximal diameter, mean  SD, range 30.5  4.3 [25-36] 30.4  4.3 [25-36] .962
Distal fixation sites (DFS)a
RCIA, LCIA 37/80 (42.5), 36/80 (45) 25/66 (37.9), 28/66 (42.4) .516/.845
REIA, LEIA 3/80 (3.8), 4/80 (5) 9/66 (13.6), 4/66 (6.1) .047/.791
Iliac axis sites requiring extension(s) 37/83 (44.6) 39/67 (58.2) .344
Bileteral extensions (per total sites) 9/83 (10.8) 16/67 (23.9) .073
Total implanted endograft parts,
mean  SD (range)
120, 2.86  0.77 (2-4) 104, 3.29  1.06 (2-5) .258c
Requirement for troubleshooting
techniques
0 7 (20.6) .0047
Intraoperative complications
Acute conversion to open repair 0 0 NA
Failed deployment 0 0 NA
Endograft misplacement (short limb
opened at CIA)
2 (4.7) 0 .213
Partial occlusion of renal artery
(50%)
0 1 (2.9) .265
Perforated EIA 1 (2.3) 0 .376
Open femoral artery repair 1 (2.3) 0 .376
Allergic reaction 1 (2.3) 0 .376
Intraoperative adjunctive procedures
(intentional/accidental or
unplanned)
Conversion to AUI and Fem-Fem
bypass
2 (4.7) 0 .213
Cross-limb technique 1/40a (2.5) 8/33a (24.2) .013
CIA or EIA angioplasty for delivery
system passage
4 (9.3) 2 (5.9) .606
CIA stent insertion 1 (2.3) 2 (5.9) .442
Total intentional/accidental occlusion
of IIA
6/83 (7.2) 14/65 (21.5) .028
IIA aneurysm embolization 1 (2.3) 2 (5.9) .442
Proximal neck balloon angioplasty
(Reliant)
41 (95.3) 31 (91.2) .892
Distal endograft parts balloon
angioplasty (Reliant)
43 (100) 34 (100) 1
Proximal aortic cuff deployment for
type Ia EL
0 2 (5.9) .118
Proximal aortic neck ballooning for
type Ia EL
0 1 (2.9) .265
Reasons for distal limb extensions
deployment
CIA aneurysm exclusion 4/83 sites (2.7) 9/67 sites (13.4) .089
Inadequate distal nonaneurysmal
iliac fixation length
30/83 sites (36.2) 24/67 sites (35.8) .978
Type Ib EL 3/83 sites (3.6) 4/67 sites (6) .517
EL at completion angiogram
Type Ia 0 3 (8.8), [10.7]b .057 [.037]b
Type Ib 3 (7) 4 (11.8) .509
Type II 3 (7) 1 (2.9) .451
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Variable
Number (%)
P valueGroup I Group II
Technical success (extended through
the first 24 hours)
41/43 (95.4) 34/34 (100) .88
Endograft limb thrombosis  24
hours
1 (2.3) 0 .376
Access site hematoma not requiring
surgical evacuation
2 (4.7) 4 (11.8) .287
Lymphocele 1 (2.3) 1 (2.9) .87
Blood transfusion units, mean
(range)
0.12  0.45 (0-2) 0.47  1.02 (0-5) .15b
Intensive care unit stay 1 (2.3) 0 .376
Postoperative platelets, mean  SD
(range)
156,220  58,284 (63,000-330,500) 172,307  75,754 (94,000-383,000) .471
Postoperative fever (unknown origin)d 9 (20.9) 19 (61.8) .032
Systemic postoperative complications
Acute mild or severe coronary
syndrome
1 (2.3) 1 (2.9) .87
Renal failure requiring temporary
dialysis
0 1 (2.9) .265
Intestinal ischemia (ileus) not
requiring intervention
1 (2.3) 0 .376
Increased D-dimers and CPK-MB
without any reason identified
1 (2.3) 0 .376
MSOF 1 (2.3) 0 .376
Ileus not requiring surgical
intervention
1 (2.3) 0 .376
Aneurysm related mortality (30
days)
1 (2.3) 0 .376
Operative deaths (30 days) 2 (4.7) 0 .213
Hospitalization dates, mean (range) 4.7  2.1 (3-15) 4.2  3 (2-19) .15c
CIA, Common iliac artery; EIA, external iliac artery; EL, endoleak; Fem-Fem, femoral-femoral cross-over bypass; IIA, internal iliac artery; L, left; MSOF,
multiple system organ failure; NA, not applicable; R, right; SD, standard deviation.
aAUI cases excluded (83 DFS for group I, 66 DFS for group II).
bWhen patients with only iliac angulation criterion (6/34) were dropped out from GII.
cMann-Whitney U test was used for continuous variables in case of non-symmetric distribution of data.
dTemperature 38o C 1 onsets for at least 2 days.
